Widely used:Recently Viewed
Clear All
$540 Mln
--
3.06
--
0.54
-52.2 %
--
--
--
-2881841
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Celcuity (CELC)
| 1.72 | -7.14 | -8.46 | 62.32 | -5.78 | -1.95 | -- |
|
BSE Sensex*
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Celcuity (CELC)
| 4.00 | 6.22 | 44.00 | -13.91 | -55.65 | 26.43 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$539.90 Mln
$0.23 Mln
$0.00 Mln
$283.07 Mln
$96.51 Mln
High
$8.39 - 22.19
37,030,200
NASDAQ: CELC
Minneapolis, MN
https://www.celcuity.com
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to... identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Address: 16305?36th Avenue North, Minneapolis, MN, United States, 55446 Read more
The total asset value of Celcuity Inc (CELC) stood at $ 312 Mln as on 30-Jun-24
The share price of Celcuity Inc (CELC) is $14.82 (NASDAQ) as of 03-Oct-2024 16:29 EDT. Celcuity Inc (CELC) has given a return of -5.78% in the last 3 years.
Celcuity Inc (CELC) has a market capitalisation of $ 540 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Celcuity Inc (CELC) is 3.06 times as on 02-Oct-2024, a 2% discount to its peers’ median range of 3.12 times.
Since, TTM earnings of Celcuity Inc (CELC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Celcuity Inc (CELC) and enter the required number of quantities and click on buy to purchase the shares of Celcuity Inc (CELC).
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Address: 16305?36th Avenue North, Minneapolis, MN, United States, 55446
The CEO & director of Mr. Brian F. Sullivan. is Celcuity Inc (CELC), and CFO & Sr. VP is Mr. Brian F. Sullivan.
There is no promoter pledging in Celcuity Inc (CELC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
996
|
|
|
994
|
|
|
980
|
|
|
819
|
| Celcuity Inc. (CELC) | Ratios |
|---|---|
|
Return on equity(%)
|
-52.2
|
|
Operating margin(%)
|
-36391.42
|
|
Net Margin(%)
|
-35962.55
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Celcuity Inc (CELC) was $0 Mln.
$0.15
